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Abstract
Opioid abuse and addiction affects more than 2.4 million people in the United
States. Medication assisted treatment (MAT), in combination with counseling, is
recognized as the most effective treatment for patients with opioid dependence and
abuse. Although MAT is considered the most effective treatment, previous research
has found clinically significant weight gain with methadone. The purpose of this
study was to determine if hedonic eating behaviors, sugar cravings, and addictive like
eating was related to weight gain in opioid addicted patients receiving methadone and
buprenorphine/naloxone (Suboxone™). Hedonic eating behaviors were measured
using three validated surveys. Following survey collection, a chart review was
completed to determine weight changes over time. One hundred twenty surveys were
completed and 113 were analyzed. No differences were found between the
medication groups in terms of mean age, weight at entry, BMI at entry, race, sex, and
Hepatitis C status. A subset of 39 participants was analyzed for weight changes
during treatment. There were no differences in food addiction scores, hedonic eating
behaviors, and food cravings between the medication groups. We found significant
weight gain in patients receiving methadone and no weight changes for those
receiving Suboxone™. Weight gain in methadone maintenance does not appear to be
related to addictive like eating, food craving, or hedonic eating. This research
suggests that weight gain seen in methadone maintenance for opioid addiction
treatment is related to something other than hedonic eating behaviors. Clinically
significant weight gain should be considered when prescribing methadone for opioid
addiction.
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Introduction
Opioid abuse and addiction affect over 2.4 million people in the United States. In
2014, 1.9 million people abused prescription pain medication and 586,000 people were
addicted to heroin (Substance Abuse and Mental Health Services Administration, 2015).
In Vermont alone, nearly 4,000 people are currently in treatment for opioid addiction
(Vermont Department of Health, 2014). Medication assisted treatment (MAT), in
combination with counseling, is recognized as the most effective treatment for patients
with opioid dependence and abuse (Stotts, Dodrill, & Kosten, 2009). However, Fenn,
Laurent, and Sigmon (2014) found a mean increase of 17.8 pounds for patients following
entry into methadone treatment within, on average, the first 18 months of treatment.
Although research supports the use of MAT for opioid addiction, the implications for
weight gain are significant. Obesity is associated with higher risk for many serious
diseases and health conditions including hypertension, type II diabetes, stroke, anxiety,
depression, heart disease, and overall mortality (CDC, 2014).
Methadone is a mu-opioid agonist (Yaksh &Wallace, 2011). In a systematic
review, Mysels and Sullivan (2010) found that mu-opioid receptor activation is
associated with increased preference for sweets, hyperglycemia, and potential insulin
resistance. There is a growing body of research demonstrating that particular foods and
food additives act on similar neural pathways as addictive drugs (Gearhardt et al., 2011).
The literature also suggests that food addiction or addictive like eating is a contributing
factor to obesity (Blumenthal & Gold, 2010). Methadone is associated with significant
weight gain, however, the mechanisms of this weight gain are not fully understood.
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Volkow et al. (2002) describe neural pathways in individuals with food addiction
consistent with neural pathways found in individuals with opioid addiction. It is plausible
that some of the weight gain seen in methadone treatment for opioid addiction might be
attributable to hedonic preferences toward highly sweetened foods.
Additionally, substitute addiction, the process of replacing one addictive or
compulsive behavior with another (McFadden, 2010), might be a plausible mechanism
for increased food consumption and weight gain in methadone treatment. The literature
on substitute addiction posits that for a substitute addiction to occur, the new compulsive
behavior must replace at least one key function, such as pleasure or escape, previously
achieved by a former addiction (Sussman & Black, 2008). This study may provide
additional evidence into the potential contribution of substitute addiction and addictive
like eating in medication assisted treatment for opioid addiction.
It is unclear if buprenorphine, a partial mu-opioid agonist used in the treatment of
opioid addiction, has similar effects as methadone on weight gain. Buprenorphine is
increasingly used in addiction treatment in the primary care setting. Because
buprenorphine and methadone affect the mu-opioid receptor differently, understanding
weight changes in buprenorphine treatment compared to methadone may provide insight
into overall hedonic mechanisms of weight gain in MAT. If differences between the two
drugs in weight gain are determined, the weight gain may be more attributable to the drug
side effects than to eating behavior. If, however, similar weight trends are observed
between the two drugs, it is plausible that eating behavior is implicated in weight gain in
MAT regardless of the medication used in treatment.

	
  

2	
  

	
  
Purpose of the study
The aim of this study is to determine the relationship between hedonic eating
behaviors, sugar cravings, and weight gain in opioid addicted patients receiving
medication assisted treatment. A secondary aim is to determine if there is a difference
between weight gain and hedonic eating behaviors for individuals undergoing methadone
compared to buprenorphine treatment. Our hypothesis is that hedonic eating behaviors
and addictive like eating will be associated with weight gain in medication assisted
treatment for opioid addiction for both methadone and buprenorphine. Despite the
hedonic mechanisms, we expect greater weight gain in those receiving methadone than
those receiving buprenorphine based on the pharmacodynamics of the drugs.
Theoretical framework
Robinson and Berridge’s Incentive-Sensitization Theory will be utilized to inform
study design and procedures. The theory suggests that in certain individuals with repeated
exposure to a stimulus, a hypersensitivity response occurs in the brain and transforms the
perception of that stimulus into pathological wanting. This pathological wanting is known
as incentive salience. In certain individuals, repeated exposure to addictive drugs can
alter the neural systems responsible for incentive salience to make an individual
hypersensitive or sensitized to that drug and associated stimuli. This results in pathologic
attachment to the drug and associated stimuli. Drug ‘wanting’ is then transformed into
excessive drug craving. This can occur independently of the neural systems that mediate
the pleasurable (‘liking’) and withdrawal effects of drugs, meaning that drug seeking may
occur in absence of withdrawal or pleasure. As a result, addictive behaviors such as of
compulsive drug seeking and taking occur despite strong desires to quit and
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consequences of continued use. Neural adaption recurs and is responsible for drug
wanting, which may last for years even after discontinued use (Robinson & Berridge,
1993, Robinson & Berridge, 2008). Recent literature suggests that certain foods and food
additives may trigger addictive process in the brain similar to those seen in drug addiction
(Gearhardt, Corbin, & Brownell, 2008), suggesting similar pathological wanting.
Significance
With the potential obesity related health problems patients recovering from drug
addiction may face, understanding the mechanism behind weight gain is essential in order
to provide optimal care, minimize risks, and impart the most appropriate education for
patients. A clearer understanding of the mechanisms of weight gain in MAT can alter
treatment paradigms for nurse practitioners and other clinicians. The information gleaned
from our study has the potential to create recommendations for a multidisciplinary
treatment approach that includes nutrition support, mental health services, social service
resources, and food and addiction counseling. This research will provide further
understanding of the relationships among these phenomena and, in particular, of the
hedonic mechanisms of weight gain in medication assisted treatment for opioid addiction,
and may contribute to future research aimed at gathering empirical evidence on substitute
addiction.
APRN Competencies
Several nurse practitioner core competencies as outlined by the National
Organization of Nurse Practitioner Faculties are addressed within this study including
scientific foundation, leadership, practice inquiry, policy, and ethics (NONPF,	
  2012).
The information discovered from this study has the potential to enhance the scientific
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foundation from which advanced practice registered nurses (APRNs) practice in primary
care by furthering the understanding of the implications and side effects of MAT.
Advanced practice registered nurses provide direct care to individuals receiving MAT
and may, in the future, be prescribers of MAT. Advanced practice registered nurses are in
a key position to be leaders in addressing the ongoing opioid and obesity epidemics. It is
expected that the study findings will be applicable to a broad inter-professional audience
that provides full spectrum care to this underserved, high-risk population, furthering the
policy, ethical, and leadership impacts.
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Comprehensive Literature Review
This chapter outlines the current literature related to weight gain in patients
receiving methadone for opioid addiction, sugar cravings in medication assisted treatment
(MAT), and food addiction. It concludes by proposing a hypothesis for substitute
addiction as a plausible mechanism for weight gain seen in MAT. At the time this
literature review was prepared, the weight effects of buprenorphine were absent from the
literature.
Weight changes in medication assisted treatment
A 2005 study evaluated body mass index (BMI) and adiposity of opioid addicted
patients (n=30) before treatment and after four years of treatment with methadone. The
study compared BMI and mid arm muscle circumference (MAMC) in patients in
treatment for opioid addiction. At the four-year follow-up, female patients (n=7) had a
decrease in BMI with the percentage of fatty tissue in general body mass significantly
below recommended values. In male patients (n=23), BMI increased with a concurrent
increase in MAMC. This suggested that weight changes in methadone treatment may
differ by gender. The study may not be generalizable to a US population and was
significantly limited by its small sample size. Little statistical generalizability can be
gleaned from the female population based on the sample size (Kolarzyk et al., 2005).
Despite these limitations, this study provided early insight to potential differential effects
of weight gain in men receiving methadone treatment.
In a retrospective chart review, Fenn, Laurent, and Sigmon (2014) examined
changes in body mass index (BMI) among patients participating in methadone treatment
for opioid addiction. Health records of 96 non-pregnant, opioid-dependent adults enrolled
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in an outpatient methadone treatment program for at least 6 months between 2002-2011
were analyzed. Significant increases in BMI were found following entry into methadone
treatment. The mean BMI increased from 27.2 to 30.1 kg/m2, representing a mean weight
gain of 17.8 lbs. A significant difference between female and male weight gain was
observed with female patients gaining on average of 28 pounds compared to men who
had an average increase of 12 pounds. Collectively, this represented clinically significant
weight gain (Donnelly et al., 2009). This study provided evidence that methadone may
contribute to weight gain, but the mechanisms behind the weight gain were not
addressed. These findings were in contrast to Kolarzyk et al. (2005) who reported a
decrease in adiposity in females. The sample size was small (n=7) which may explain this
descrepency. Confounding medication use was not isolated.
Mysels et al. (2011) conducted a retrospective chart review to compare weight
changes in patients on naltrexone compared to methadone. Health records of 36 opioiddependent patients within the first six months of treatment were reviewed. Both groups
showed significant weight gain compared to baseline weight. At six months, the
methadone maintained group had a mean increase in weight of 3.67% and the naltrexone
group had a 4.63% increase compared to baseline. There was no statistically significant
difference between the groups in weight gain at xix months. Strengths of this study
include that it compared both treatments. The sample size was small, which limited the
power of the study. The study was also limited in that it compared different clinics each
with different treatment protocols. Although the data was limited, these results suggest
that medication side effects alone may not account for weight gain found in medication
assisted treatment. If so, one would expect to see differing weight gain between the
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methadone and naltrexone. Similarly, if weight gain on methadone maintenance was
attributable to an increase in sugar cravings alone, one would not expect to see an
increase in weight with administration of an opioid antagonist such as naltrexone. This
may suggest hedonic mechanisms as a potential etiology of weight gain in MAT
regardless of drug.
Okruhlica and Slexakova (2012) explored the question of whether weight gain
with methadone maintenance treatment was stable over time or transitory. The authors
also examined the possible contributions of pharmacological and sociologic factors on
body weight changes in methadone maintenance treatment. This longitudinal,
observational study included 42 patients participating in a methadone maintenance
program in Slovakia. Significant increases in mean BMI change were seen after one year
and a less significant increase between one and two years. Further, no statistically
significant weight changes were found between one and four years after entry into
treatment. These findings suggest weight gain is more significant in the first year of
treatment and plateaus after year two. No association was found between amount of
weight gain and dose of medication. This lack of association adds evidence suggesting
eating behavior and sociologic factors might play more of a role in the weight gain than
the pharmacological factors, particularly early in treatment.
Parvaresh, Sabahi, Mazhari, and Gilani (2015) investigated the effects of
methadone treatment on sexual function, sleep, and weight after six months of MAT. The
cross-sectional study used a convenience sample of patients (n=199) from a methadone
clinic in Iran. Patients were weighed at the beginning and end of treatment. Additionally,
all patients completed demographic questionnaires, sleep and sexual experience
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evaluations. Patients weight significantly increased compared to baseline over the course
of the 6-months in methadone maintenance treatment (MMT). The incidence of sexual
dysfunction and sleep disorders also significantly increased with MMT. This study
examined a larger sample size than many previous studies. The results are comparable
with other studies suggesting an increase in weight for both male and female patients
receiving methadone maintenance. The study also highlights other important side effects
of methadone to consider while providing patient counseling.
In summary, patients receiving methadone for opioid addiction demonstrate
significant weight gain. However, the exact mechanisms of this remain unclear. Lack of
comparison studies using buprenorphine make it difficult to determine if weight gain is
related to recovery, medication, or other mechanisms. Mysels et al. (2011) found similar
weight gain for naltrexone and methadone. Although Kolarzyk et al. (2005) found a
decrease in BMI in female patients, it should be noted that the sample size was very small
(n=7). More recently published studies with larger sample sizes have shown increase in
BMI for both female and male patients, one showing a significantly higher increase in
BMI in females than in males (Fenn et al., 2014). Weight gain among methadone patients
was clinically significant.
Sugar cravings in opioid use
Cirello et al. (1987) conducted an early case control study examining plasma
glucose and insulin responses to oral and intravenous glucose administration in users of
heroin and methadone compared to healthy controls. Both heroin and methadone users
had altered response to the oral and IV glucose load compared to the case controls with
lower fasting plasma glucose and significantly higher basal insulin than controls. The
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acute insulin response in the methadone and heroin users was significantly less than the
controls. Both groups of opioid users also had increased fasting insulin levels. This
provided early evidence that heroin and methadone addiction may alter glucose
metabolism in a pattern similar to what is observed in individuals with non-insulin
dependent diabetes. Altered glucose metabolism may contribute to weight gain seen in
opioid addiction. Limitations included that the study was relatively small and lack of
matched comparison group.
Nolan and Scagnelli (2007) conducted a pilot study to examine food preferences
and eating habits in patients receiving methadone treatment. Food preference and eating
habit questionnaires were distributed to participants receiving outpatient methadone
maintenance treatment (n=28) and controls (n=14). Patients on methadone reported
higher consumption of sweets, higher eagerness to consume sweet foods, and a wish to
consume larger quantities than healthy controls. In addition to reporting higher
consumption of sweet foods, methadone patients had higher BMIs overall than controls,
suggesting a link between methadone, an increased cravings and consumption of sweet
calorically dense foods, and weight gain. There were several limitations of this study
including its small sample size with unmatched controls, the food craving instruments
used were not validated, and height and weight were self reported. Despite these
limitations, this study provides important preliminary information about potential
mechanisms of weight gain in methadone treatment including preferences for sweets and
increased consumption of such foods.
Mysels and Sullivan (2010) conducted a literature review to explore the
relationship between opioid use and development of preference for sweet tastes and
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associated dental pathology, weight gain, and loss of glycemic control. The review
included studies with patients using heroin and patients receiving methadone treatment.
No studies were included that examined patients who exclusively abused prescription
opioids. They found activation of the mu-opioid receptor by methadone or heroin was
associated with increased palatable (sweet) taste preference, weight gain, and tooth
decay. Opioid use was also associated with increased hyperglycemia induced by direct
action on pancreatic islet cells, which has been shown to increase dietary preference for
sugary foods and associated increased insulin resistance (Reed & Ghodse, 1973;
Willenbring et al., 1989). Opioid antagonists were not associated with weight gain or
glycemic dysregulation. Methadone maintained patients were found to be especially
susceptible to weight gain, poor dentition, and diabetes. Studies that examined
buprenorphine effects on weight were not included due to a lack of research in this area.
This study provides important evidence to the association of sweet taste preference,
weigh gain, and methadone maintenance. This further supports that hedonic mechanisms
may be implicated in weight gain in methadone maintenance treatment for opioid
addiction.
Food addiction and hedonic eating
Through the advancement of imaging technologies, much more is understood
about the brain activity in addiction. Recent literature suggests that certain foods and food
additives may trigger addictive processes in the brain similar to those seen in individuals
with drug addiction. Drugs and food both trigger reinforcing pathways mediated by
dopamine in the meso-limbic system (Gearhardt, Corbin, & Brownell, 2008).
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Volkow et al. (2002) examined the role of dopamine in “nonhedonic” food
motivation. Participants (n=10) were shown pictures of food after being food deprived for
16-20 hours. The response was monitored through positron emission tomography (PET)
and raclopride, a dopamine receptor radioligand that binds to the dopamine receptor and
competes with endogenous dopamine. Subjects were pretreated with methylphenidate in
order to block the dopamine transporter and amplify any dopamine changes. Food cues,
in combination with methylphenidate, were associated with an increase in extracellular
dopamine in the dorsal striatum. The dorsal striatum mediates decision-making,
especially action selection and initiation (Balleine, Delgado, & Hikosaka, 2007). Food
cues and increase in extracellular dopamine were associated with increased self-reports of
hunger and desire for food. This suggests that dopamine in the dorsal striatum is
involved in food motivation. No change was seen in the ventral striatum, including the
nucleus accumbens (NA). This suggests that dopamine in the dorsal striatum is involved
in food motivation distinct from dopamine’s role in food motivation related to the NA
and reward system. Food was not consumed in this study suggesting that without food
consumption, the reward system associated with those stimuli were not activated.
A 2011 study examined the neural correlates of addictive-like eating using
functional magnetic resonance imaging (fMRI) in healthy adults. Forty-eight healthy
women were recruited with BMIs ranging from normal to obese. Participants with eating
disorders were excluded. Food addiction scores were compared to fMRI brain activation
in response to receipt and anticipation of palatable food. Females meeting the threshold
for food addiction showed similar brain activation on fMRI as was seen in individuals
with drug addiction – including activation of reward circuitry (dorsolateral prefrontal
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cortex and caudate, anterior cingulate cortex, medial orbitofrontal cortex, and amygdala)
and reduced activation of inhibitory regions (lateral orbitofrontal cortex) in response to
anticipation of food. There was no significant correlation found between food addiction
scores and BMI. Although the sample size was small, this was the first study to look at
the relation between food addiction and neural reward activation. Activation of the neural
rewards system suggests a similar process in the brain in response to food as is found in
drug addiction (Gearhardt, et al., 2011). It is plausible that individuals who have greater
susceptibility to drug addiction might also be more susceptible to food addiction due to
the similar neural pathways and processes.
Stojek, Fisher, and MacKillop (2015) utilized drug addiction paradigms to
understand eating behaviors and motivations for high sugar, high fat food consumption.
This study utilized an experimental design and well documented addiction paradigm.
Subjective cravings, relative reinforcing value of foods (RRVfoods), negative and positive
affect, amount of food consumed, and latency to first bite were measured following
exposure to food cues. Adults (n=133) who endorsed liking high fat, high sugar snacks
and denied eating pathology were recruited. Participants were randomly assigned to one
of two mood conditions – stress or neutral and to one of two cue exposure conditions –
food cues or neutral cues (office supplies). Participants in the stress condition reported no
change in craving or in RRVfoods,. Food cues increased participants cravings and
RRVfoods. No interaction was found between stress and food cues. Calories consumed
were not different in subjects in either the stress or food cues conditions, but those in the
food cues condition had shorter latency to first bite. The addiction literature suggests
guided imagery does not elicit cravings in social drinkers only in those with alcohol use
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disorder. Only adults without eating pathology were included, therefore the results may
not be generalizable to a population with eating pathology. No biomarkers such as
cortisol were collected. This study underlines the role that food cues play in food
motivation, suggesting that increased food cues created a higher risk for overeating.
Gearhardt, Corbin, & Brownell (2009) examined the food addiction literature in
the context of each diagnostic criterion for dependence in the Diagnostic and Statistical
Manual of Mental Disorders (4th ed., text rev.; DSM-IV-TR; American Psychiatric
Association, 2000). The diagnostic criteria for substance dependence in the DSM-IV
consisted of: tolerance; withdrawal; taking the substance in larger amounts or over a
longer period than was intended; persistent desire or unsuccessful effort to cut down or
control substance use; spending a great deal of time in activities necessary to obtain or
use the substance or to recover from its effects; giving up social, occupational, or
recreational activities because of substance use; and continuing the substance use with the
knowledge that it is causing or exacerbating a persistent or recurrent physical or
psychological problem. The review found increasing evidence to support that a subset of
people lose control over eating, are unable to abstain from certain types of foods in spite
of negative consequences, and fail at attempts to reduce intake. The other categories of
dependence (i.e. tolerance, withdrawal, spending a great deal of time in activities
necessary to obtain or use the substance or to recover from its effects, and giving up
social, occupational, or recreational activities because of substance use) have less clear
evidence from which to draw conclusions. Collectively, it appears the evidence suggests
that addictive-like eating may affect a subset of individuals.
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Jasinska et al. (2012) explored the role of impulsivity and inefficient inhibitory
control in individuals with unhealthy eating behaviors. Structural equation modeling was
utilized to explore in-depth relationships among impulsivity, inhibitory control, eating
behavior, and body mass index. Undergraduates (n=210) with BMIs ranging from
underweight to obese were recruited. Impulsivity and inhibitory control deficits were
associated with overeating in response to food cues, negative emotional states, and
making food choices based on health preferences - not health value. Participants with
lower inhibition were more likely to eat more unhealthy foods and had lower intake of
healthy foods. Unhealthy eating behaviors and choices were associated with an increased
BMI. This suggests there similar biological mechanisms involve in food and drug
addiction. Impulsivity and inhibitory control deficits may put individuals at higher risk
for both drug and food addiction.
How prevalent is substitute addiction?
Substitute addiction, also known as addiction transfer or cross-addiction, is a
phenomenon that occurs when a person replaces one compulsive behavior that causes
impairment with another (McFadden, 2010). Sussman and Black (2008) describe
substitute addition as “any addictive behavior that serves at least one key function
previously achieved by another addictive behavior (e.g., relaxation, escape, excitement,
pleasure, reduction of negative affect, social lubrication).” Although there have been
anecdotal discussions of substitute addiction in the recovery community, there is little
empirical research on the topic. In a 2007 literature review, 27 webpages on a Google
Scholar search and 2 articles in a search of OvidMEDLINE and PsycINFO were found on
the topic (Sussman & Black, 2008). As early as 1966, the concept of substitute addiction
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was being discussed in the literature. One of the earliest studies on the topic by Valiant
(1966) included food, in addition to marijuana, chloriazepoxide, religion, and
participation in alcoholics anonymous, as common substitute addictions in narcotic
abusers. A 2012 literature review found an increase in the prevalence of eating disorders
in particular bulimia nervosa in patients with concomitant drug use disorder compared to
the general population (Nøkleby, 2012).
In a retrospective chart review, Kleiner et al. (2004) examined the relationship
between obesity and alcohol consumption. An inverse relationship was found between
BMI and alcohol consumption in women (n=298) who were in active weight
management. Obese patients had lower rates of alcohol use than the general population.
The authors hypothesize that overeating may compete with alcohol in the reward system
in the brain, suggesting that one substance may be able to replace another in the reward
circuit of the brain.
Although the empirical evidence on substitute addiction is limited, there is
significant anecdotal support of this phenomenon in the recovery literature. Utilizing this
framework, it is plausible that food addiction may serve as a substitute addiction for those
in recovery for opioid addiction and food may fill one or more key functions (relaxation,
pleasure, escape, etc) that opioid addiction had previously served for patients. These key
functions might be related to the reward pathway in the meso-limbic dopamine reward
circuit. It is also plausible that those who are more susceptible to drug addiction may be
more susceptible to food addiction both in terms of brain chemistry as well as impulsivity
and inhibitory control. The research suggests a relationship between methadone use and
weight gain; opioid intake appears to correlate with increased sugar intake; and food
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addiction follows similar pathways in the brain to opioid addiction. The proposed
research will provide further understanding of the relationships among these phenomena
and, in particular, of the hedonic mechanisms of weight gain in medication assisted
treatment for opioid addiction. In addition, it may contribute to future research aimed at
gathering empirical evidence on substitute addiction.
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Hedonic Mechanisms of Weight Changes in Medication Assisted Treatment for
Opioid Addiction
Abstract
Background and purpose: Opioid abuse and addiction affects more than 2.4 million
people in the United States. Medication assisted therapy (MAT) with methadone or
buprenorphine, along with behavioral counseling, is considered the most effective
treatment for opioid use disorders. Previous research has found clinically significant
weight gain with methadone treatment for opioid addiction, but the mechanisms behind
weight gain remain unclear. The purpose of this study was to determine if hedonic eating
behaviors, sugar cravings, and addictive like eating was related to weight gain in opioid
addicted patients receiving buprenorphine/naloxone (Suboxone™) and methadone.
Methods: Patients undergoing MAT (n=113) completed three questionnaires to measure
hedonic eating and sugar craving. A chart review was completed to determine baseline
weight and weight changes over time. Results: No differences were found between the
medication groups in terms of mean age, weight at entry, BMI at entry, race, sex, and
smoking and Hepatitis C status. A subset of 38 participants was analyzed for weight
changes over time. Weight gain in patients receiving methadone was evident with no
weight changes for those receiving Suboxone™. There were no differences in food
addiction scores, hedonic eating behaviors, and food cravings between the medication
groups. Both medication groups demonstrated higher levels of cravings and “giving in”
to those cravings for sweets than for fats. Conclusions: Our findings demonstrate that
individuals receiving methadone for MAT have greater weight gain than individuals
receiving Suboxone™. The groups had similar eating behaviors suggesting that weight
gain associated with methadone may not be attributable to hedonic eating.
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1. Introduction
Opioid abuse and addiction affect over 2.4 million people in the United States. In
2014, 1.9 million people abused prescription pain medication and 586,000 people were
addicted to heroin (Substance Abuse and Mental Health Services Administration, 2015).
Medication assisted therapy (MAT), in combination with counseling, is recognized as the
most effective treatment for patients with opioid use disorders (Stotts, Dodrill, & Kosten,
2009). Both buprenorphine and methadone maintenance have been shown to reduce rates
of illicit drug use, deaths from overdose, risky behavior linked to HIV and Hepatitis C
transmission, crime, and overall mortality (Thomas et al., 2014). Although research
supports the use of MAT for opioid addiction, it is not without adverse effects. Several
studies document clinically significant weight gain (i.e. >5% of baseline) as a side effect
associated with methadone maintenance posing additional risks unrelated to substance
addition (Mysels et al., 2011; Fenn et al., 2014). Obesity is associated with higher risk for
many serious diseases and health conditions including hypertension, type II diabetes,
stroke, anxiety, depression, several types of cancers, heart disease, and overall mortality
(Centers for Disease Control, 2014). Further, a 5% increase in weight from baseline
increases risk of hypertension, hyperlipidemia, diabetes, and heart disease (Donnelly et
al, 2009).
The exact mechanisms associated with weight gain for individuals receiving
methadone maintenance remain unclear. Weight changes associated with
buprenorphine/naloxone (Suboxone™) have not been documented. Methadone’s strong
affinity for the mu-opioid receptor makes it highly effective in MAT. However,
preclinical trials from animal studies suggest that agonism of the mu-opioid receptor in
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certain areas of the brain, specifically in the nucleus accumbens, hypothalamus, and
paraventricular nucleus, may increase the craving for and consumption of sugar rich
foods and certain carbohydrates (Mysels et al., 2010). Further, clinical studies have
shown methadone maintained patients report increased consumption of highly-sweetened
foods (Kolarzy et al., 2005). Similar findings regarding sugar craving, sugar
consumption, and weight gain associated with Suboxone™ are not well documented.
There is a growing body of research demonstrating that particular foods and food
additives, including sweets, act on similar neural pathways as addictive drugs (Gearhardt
et al., 2011; Volkow et al., 2002). Gearhardt et al. (2011) examined neural pathways of
addictive like eating in women using functional magnetic resonance imaging (fMRI).
Participants meeting the threshold for food addiction showed similar brain activation on
fMRI that is seen in individuals with drug addiction – including activation of reward
circuitry (dorsolateral prefrontal cortex and caudate, anterior cingulate cortex, medial
orbitofrontal cortex, and amygdala) and reduced activation of inhibitory regions (lateral
orbitofrontal cortex) in response to anticipation of food. It is plausible that some of the
weight gain seen in methadone maintenance might be attributable to hedonic preferences
toward highly sweetened foods. Agonism of the mu-receptor in these key neural reward
pathways may potentiate the hedonic response for sweet foods and beverages.
Differences between the binding properties of buprenorphine and methadone might
explain the anecdotal reports of sugar cravings in methadone but not in
buprenorphine/naloxone.
The purpose of this study was to determine if hedonic eating behaviors, sugar
cravings, and addictive like eating were related to weight gain in opioid addicted patients
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receiving medication assisted therapy. A secondary aim was to determine differences
between weight gain and eating behaviors for individuals receiving methadone compared
to individuals receiving Suboxone™ for MAT. Our hypothesis was that hedonic eating
behaviors and increased food addiction symptom scores would be associated with weight
gain in medication assisted treatment for opioid addiction for both methadone and
Suboxone™. Despite the hedonic mechanisms, we expected greater cravings for sweets
and carbohydrates and higher associated weight gain in individuals receiving methadone
compared to those receiving Suboxone™.
2. Methods
Patients enrolled in medication assisted treatment for opioid addiction in an
outpatient treatment facility in the northeastern United States were recruited for this
study. Inclusion criteria consisted of: English speaking individuals 18 years of age and
older receiving either methadone or buprenorphine/naloxone (Suboxone™) daily,
receiving treatment for at least six months, and who were at a stable medication dose.
Exclusion criteria included women who were pregnant and breastfeeding women while
receiving MAT.
Following informed consent, participants completed three validated eating
behavior surveys. A chart review was conducted. Demographic data (i.e age, gender,
ethnicity), height and weight upon entry into treatment, most recent weight, weight time
interval, MAT medication (methadone or Suboxone™), medication dose, other
concurrent medications, smoking status, and duration in program were collected. This
study was approved by the University’s Institutional Review Board prior to the onset of
the study.
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2.1 Measures
The Food Craving Inventory (FCI) (White et al., 2002) is a validated 28-item selfadministered instrument used to determine specific food cravings. It was developed using
two subscales: subjective cravings and consumption of particular foods. Subjective
cravings were found to correlate with consumption. Frequency of cravings is rated on a
5-point Likert scale ranging from 1 (“not at all”) to 5 (“nearly every day”). The inventory
contains four scales that measure high fats, sweets, carbohydrates/starches, and fast-food
fats.
The Yale Food Addiction Scale (YFAS) (version 2.0, Gearhardt, Corbin, & Brownell,
2009) is a validated 25-item self-report questionnaire. It is used to identify symptoms of
addictive-like eating and food addiction. Food addiction is present when three or more
symptoms of addictive like eating are endorsed and at least one of two of clinical
significance items (i.e impairment or distress) are endorsed (Gearhardt, Corbin, &
Brownell, 2009).
The Power of Food Scale (PFS) (Lowe et al., 2009) is a validated 15-question selfadministered questionnaire used to evaluate the impact food-abundant environments by
evaluating appetite for palatable foods. It assesses the psychological impact independent
of homeostatic hunger. Higher scores suggest greater appetitive responsiveness (Laurent
& Sibold, 2016; Lowe et al., 2009).
2.2 Analysis
T-tests were computed to compare means of continuous variables between medication
groups for age, weight at entry, body mass index (BMI) at entry, addictive like eating,
appetitive responsiveness, and food craving. Chi-sqaure tests were used to compare
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differences in race, sex, smoking status, Hepatitis C status, and the presence or absence of
food addiction between the two medication groups. T-test was used to compare mean
BMI change and mean weight change between medication groups. Analysis of
covariance was computed to determine if BMI and weight change were associated with
length of time in treatment, food craving, appetitive responsiveness, and food addiction
scores, and if those associations were different between medication groups. Significance
was set at α=.05, two sided. Data was analyzed using SPSS v. 23 (IBM Corp, 2015).
3. Results
One hundred twenty surveys were completed. One hundred thirteen
(methadone=63, Suboxone™= 50) met inclusion criteria and were analyzed. Those that
were omitted were excluded based on the following: two participants received only
buprenorphine (Subutex™), two were excluded for duplicate data, and three were
excluded for treatment duration less than six months. Baseline and follow up BMI data
was available for 38 participants (methadone=29, Suboxone™=9) and was analyzed for
weight and BMI changes over time. One participant from the Suboxone™ group was
excluded from sub-group analysis for a reported weight loss of 50 pounds in two months.
Patient characteristics are presented in Table 1. Medication groups were not
statistically different for mean age, weight at entry, and BMI at entry. There were no
between group differences for sex, race, smoking status, and Hepatitis C status. Patients
receiving methadone had significant increase in BMI and weight. Sub-group analysis
using Levene’s test assuming unequal variances (p < 0.01) demonstrated a mean BMI
increase of 1.37 kg/m2, (p<0.05) translating to a mean increase of 10.48 pounds (p<0.01)
in the methadone group over the course of an average of 16 months. Patients receiving
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Suboxone™ did not have significant change in BMI (p>0.9) over time.
No significant differences were found between the MAT groups for YFAS
symptoms count, food addiction, food craving/give in sub scores and aggregate scores,
and appetitive responsiveness. Participants in both medication groups had significantly
higher cravings and gave into these cravings (p<0.01) more frequently for sugars than for
fats.
4. Discussion
Our findings indicate that individuals receiving methadone for MAT have
significant weight gain during treatment. Conversely, receiving Suboxone™ maintenance
was weight neutral. The average weight gain in the methadone group was 6%, which is
clinically significant and associated with an increased risk of hypertension,
hyperlipidemia, diabetes, and heart disease (Donnelly et al, 2009). The range of weight
change was from -20 to 48 pounds. Our findings are consistent with previous studies
showing gain in methadone maintenance. For example, Mysels et al. (2011) reported a
10-pound weight gain in the first six months of methadone MAT. Fenn et al. (2014)
found a 17.8-pound weight gain within approximately the first two years of treatment.
Okruhlica and Slexakova (2012) found that weight gain attributed to MAT plateaued at
approximately 2 years following the initiation of methadone MAT. Although our data
showed similar weight gain overall, the weight changes observed in our sample we did
not find a significant relationship between time in treatment and methadone MAT
reported in previous studies. This may be attributed to our small sample size between
groups and the variability of time between such measurements (1.25-71 months).
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Previous research suggested that patients enter opioid treatment underweight and
malnourished (Gronbladh & Ohlund, 2011; Okruhlica & Slezakova, 2008) and have
attributed in-treatment weight gain associated with methadone treatment to an overall
improvement in nutritional status. The mean BMI at entry into treatment was 27.0 kg/m2
for the methadone group and 25.2 kg/m2 for the Suboxone™ group, meaning that
individuals were overweight upon initiating MAT. This is consistent with more recent
research by Fenn et al. (2014) who found patients initiating treatment, on average, are
overweight rather than underweight. Thus, clinical consideration should be given when
prescribing methadone to an already overweight population. Given the more current
research and the ongoing obesity epidemic using methadone MAT may be creating
additional obesity related health risks to a population that is already high risk of comorbidities associated with substance dependence and addiction.
We were unable to isolate predictors of weight gain. Thirty eight percent of
individuals receiving methadone had clinically significant weight gain. Those with
clinically significant weight change gained, on average, greater than 28 pounds. This
suggests that a subset of individuals may be more susceptible to weight gain and the
weight gain for these individuals may be greater than suggested by mean weight change
of the entire sample. Further research is indicated to determine predictors of weight gain
during treatment. Proposed mechanisms include genetics, physical activity, and
individualized response to drug pharmacodynamics.
Interestingly, we did not find any relationship between hedonic eating, appetitive
responsiveness, and addictive like eating in either the methadone or Suboxone™ groups.
Our original hypothesis that hedonic eating was a contributing factor to weight gain more
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specifically in the methadone MAT was not supported. Previous research and anecdotal
reports from individuals receiving methadone MAT suggests that such individuals have
an increased preference for sweet foods. Mysels et al. (2010) reported that individuals
using both methadone and heroin showed increased preference for sweet tastes and
associated dental pathology compared to healthy controls. Both groups had mean scores
demonstrating higher sweet cravings (i.e. sometimes to often) when compared to fat
cravings (i.e. rarely to sometimes). Participants mean scores for giving in to sweet
cravings were high (i.e. sometimes to often) for both groups compared to scores for
giving in to fat cravings (i.e. rarely to sometimes). This suggests that methadone and
Suboxone™ may both be associated with an increase in sweet preferences over other
types of palatable foods high in fat. Increased craving and giving in to such cravings of
highly sweetened foods does not appear to contribute to weight gain as previously
proposed. We, however, did not evaluate the dietary intake of our participants. Further
studies should examine craving as well as total dietary intake.
4.1 Limitations
Limitations exist. The study was limited by a small sample size. In particular,
only a small subset of participants had recorded weight information over time thus
limiting generalization of our findings. Our sample was primarily White in a rural setting
enrolled in MAT. Further, we did not evaluate other potential contributing factors such
as psychotropic medications and co-morbid conditions other than Hepatitis C that may
affect weight gain and weight status. Physical activity levels were not examined. It is
plausible that physical activity levels differ among treatment groups related to potential
drug side effects such as drowsiness and fatigue that are generally associated with
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methadone (Truven Health Analytics, 2011).
Additionally, we did not assess diet pre-treatment, and a complete food inventory,
including sugar-sweetened beverages, was not obtained. It is plausible that the foodcraving inventory utilized in this study is appropriate for a population who is comparing
craving related to opioids to that of various types of food, including sugar. The Food
Craving Inventory uses the term “cravings” to illicit an individual’s desire to consume
certain foods. The concept of craving for food, including sugar, may not be an
appropriate measure for individuals with a history of opioid cravings. Future research
should include psychometric testing in substance abusing populations. Similarly, the
Food Addiction Scale uses scoring similar to what is used to score other forms of
substance abuse. This scale may be interpreted differently by individuals with a history of
substance abuse compared to a population without a history of substance addiction.
5. Conclusions
Our findings demonstrate that individuals receiving methadone for MAT have
clinically significant weight gain whereas individuals receiving Suboxone™ do not
exhibit similar weight changes. Weight gain does not appear to be related to addictive
like eating, food craving, and appetitive responsiveness. Both groups had high mean
scores for sweet cravings when compared to other types of foods. As our sample was
overweight upon entry into MAT, individuals recovering from drug addiction who are
treated with methadone maintenance may be at greater risk for obesity and its associated
co-morbidities – thus adding one more significant health problem. As a result, potential
weight gain associated with methadone treatment should be an important clinical
consideration prior to initiating MAT. Further, patients should be informed of the
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benefits and risks of treatment, including weight gain for individuals receiving
methadone MAT. Increased attention should be directed to providing appropriate patient
education and weight-related counseling throughout MAT.
Only approximately one third of our participants had recorded weight data over
time. In order to better understand weight change in methadone and
buprenorphine/naloxone MAT, more attention should be focused on weight monitoring in
outpatient treatment. Further, longitudinal research that examines hedonic eating
behaviors during MAT would provide more insight into the mechanisms of weight
change.
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Table 1. Characteristics of Sample (N=113)*

Mean Age
Mean Weight at Entry
BMI at Entry
% Male
% Smoker
% Hepatitis C Positive

Medication

Count

Methadone
Suboxone™
Methadone
Suboxone™
Methadone
Suboxone™
Methadone
Suboxone™
Methadone
Suboxone™
Methadone
Suboxone

63
50
59
42
59
42
28
15
47
41
16
18

* not significant at p<0.05, 2 sided

	
  

32	
  

35.67
34.94
173.66
161.07
27.02
26.62
44.4%
30%
78.3%
85.4%
26.2%
37.5%

	
  

Comprehensive Bibliography
American Psychiatric Association. (2000). Diagnostic and statistical manual of mental
disorders (4th ed., text rev.). doi:10.1176/appi.books.9780890423349
Balleine, B. W., Delgado, M. R., & Hikosaka, O. (2007). The role of the dorsal striatum
in reward and decision-making. The Journal of Neuroscience, 27(31), 8161–8165.
http://doi.org/10.1523/JNEUROSCI.1554-07.2007
Blumenthal,	
  D.	
  M.,	
  &	
  Gold,	
  M.	
  S.	
  (2010).	
  Neurobiology	
  of	
  food	
  addiction.	
  Current	
  
Opinion	
  in	
  Clinical	
  Nutrition	
  and	
  Metabolic	
  Care,	
  13(4),	
  359–365.	
  
https://doi.org/10.1097/MCO.0b013e32833ad4d4	
  
	
  
Centers for Disease Control and Prevention. (2016). Adult obesity facts. CDC. Retrieved
November 8, 2016, from https://www.cdc.gov/obesity/data/adult.html
Donnelly, J. E., Blair, S. N., Jakicic, J. M., Manore, M. M., Rankin, J. W., & Smith, B. K.
(2009). Appropriate physical activity intervention strategies for weight loss and
prevention of weight regain for adults. Medicine & Science in Sports & Exercise,
41(2), 459–471. http://doi.org/10.1249/MSS.0b013e3181949333
Epocrates. (2016). Methadone pharmacology. Retrieved May 15, 2016, from
https://online.epocrates.com/drugs/5207/methadone/Pharmacology
Fenn, J. M., Laurent, J. S., & Sigmon, S. C. (2015). Increases in body mass index
following initiation of methadone treatment. Journal of Substance Abuse
Treatment, 51, 59–63. http://doi.org/10.1016/j.jsat.2014.10.007	
  
Gearhardt, A. N., Corbin, W. R., & Brownell, K. D. (2009). Food addiction: An
examination of the diagnostic criteria for dependence. Journal of Addiction
Medicine, 3(1), 1–7. http://doi.org/10.1097/ADM.0b013e318193c993
Gearhardt AN, Yokum S, Orr PT, Stice E, Corbin WR, & Brownell KD. (2011). Neural
correlates of food addiction. Archives of General Psychiatry, 68(8), 808–816.
http://doi.org/10.1001/archgenpsychiatry.2011.32
Gearhardt, A. N., Corbin, W. R., & Brownell, K. D. (2009). Preliminary validation of the
Yale Food Addiction Scale. Appetite, 52(2), 430–436.
http://doi.org/10.1016/j.appet.2008.12.003	
  
Grönbladh, L., & Öhlund, L. S. (2011). Self-reported differences in side-effects for 110
heroin addicts during opioid addiction and during methadone treatment.
ResearchGate, 13(4), 5–12.
	
  

33	
  

	
  
IBM Corp. Released 2015. IBM SPSS Statistics for Windows, Version 23.0. Armonk,
NY: IBM Corp.
Jasinska, A. J., Yasuda, M., Burant, C. F., Gregor, N., Khatri, S., Sweet, M., & Falk, E.
B. (2012). Impulsivity and inhibitory control deficits are associated with
unhealthy eating in young adults. Appetite, 59(3), 738–747.
http://doi.org/10.1016/j.appet.2012.08.001
Kleiner, K., Gold, M. S., Frostpineda, K., Lenzbrunsman, B., Perri, M. G., & Jacobs, W.
S. (2004). Body mass index and alcohol use. Journal of Addictive Diseases, 23(3),
105–118. http://doi.org/10.1300/J069v23n03_08
Kolarzyk, E., Pach, D., Wojtowicz, B., Szpanowska-Wohn, A., & Szurkowska, M.
(2005). Nutritional status of the opiate dependent persons after 4 years of
methadone maintenance treatment. Przegla̧d Lekarski, 62(6), 373–377.
Laurent, J. S., & Sibold, J. (2016). Addictive-Like Eating, Body mass index and
psychological correlates in a community sample of preadolescents. Journal of
Pediatric Health Care, 30(3), 216–223.
http://doi.org/10.1016/j.pedhc.2015.06.010
Lowe, M. R., Butryn, M. L., Didie, E. R., Annunziato, R. A., Thomas, J. G., Crerand, C.
E., Halford, J. (2009). The Power of Food Scale. A new measure of the
psychological influence of the food environment. Appetite, 53(1), 114–118.
http://doi.org/10.1016/j.appet.2009.05.016
McFadden, K. (2010). Cross-Addiction: From morbid obesity to substance abuse.
Bariatric Nursing and Surgical Patient Care, 5(2).
http://doi.org/10.1089/bar.2010.9922
Mysels, D. J., & Sullivan, M. A. (2010). The relationship between opioid and sugar
intake: Review of evidence and clinical applications. Journal of Opioid
Management, 6(6), 445–452.
Mysels, D. J., Vosburg, S., Benga, I., Levin, F. R., & Sullivan, M. A. (2011). Course of
weight change during naltrexone vs. methadone maintenance for opioiddependent patients. Journal of Opioid Management, 7(1), 47–53.
The National Alliance of Advocates for Buprenorphine Treatment. (2011). Addiction vs
physical dependence - Important distinction. Retrieved April 12, 2016, from
http://www.naabt.org/addiction_physical-dependence.cfm/	
  
NONPF. (2012). Retrieved November 11, 2016, from
http://c.ymcdn.com/sites/www.nonpf.org/resource/resmgr/competencies/npcoreco
mpetenciesfinal2012.pdf
	
  

34	
  

	
  
Nøkleby, H. (2012). Comorbid drug use disorders and eating disorders - a review of
prevalence studies. Nordic Studies on Alcohol and Drugs, 29(3), n/a.
http://doi.org/http://dx.doi.org.ezproxy.uvm.edu/10.2478/v10199-012-0024-9
Nolan, L. J., & Scagnelli, L. M. (2007). Preference for sweet foods and higher body mass
index in patients being treated in long-term methadone maintenance. Substance
Use & Misuse, 42(10), 1555–1566. https://doi.org/10.1080/10826080701517727
Okruhlica, Ĺ., & Slezáková, S. (2012). Weight changes of patients in methadone
maintenance treatment during four years period. Casopís Lékar̆ů C̆eských, 151(8),
389–391.
Olsen, C. M. (2011). Natural rewards, neuroplasticity, and non-drug addictions.
Neuropharmacology, 61(7), 1109–1122.
http://doi.org/10.1016/j.neuropharm.2011.03.010
Parvaresh, N., Sabahi, A. R., Mazhari, S., & Gilani, H. (2015). A study of the sexual
function, sleep, and weight status of patients after 6 months of methadone
maintenance treatment. Addiction & Health, 7(1-2), 24–29.
Pelchat, M. L. (2002). Of human bondage: Food craving, obsession, compulsion, and
addiction. Physiology & Behavior, 76(3), 347–352. http://doi.org/10.1016/S00319384(02)00757-6	
  
Pursey, K. M., Stanwell, P., Gearhardt, A. N., Collins, C. E., & Burrows, T. L. (2014).
The prevalence of food addiction as assessed by the Yale Food Addiction Scale:
A systematic review. Nutrients, 6(10), 4552–4590.
https://doi.org/10.3390/nu6104552	
  
Reed, J. L., & Ghodse, A. H. (1973). Oral glucose tolerance and hormonal response in
heroin-dependent males. Br Med J, 2(5866), 582–585.
http://doi.org/10.1136/bmj.2.5866.582
Robinson, T. E., & Berridge, K. C. (2008). The incentive sensitization theory of
addiction: some current issues. Philosophical Transactions of the Royal Society
B: Biological Sciences, 363(1507), 3137–3146.
http://doi.org/10.1098/rstb.2008.0093
Robinson, T. E., & Berridge, K. C. (1993). The neural basis of drug craving: An
incentive-sensitization theory of addiction. Brain Research Reviews, 18(3), 247–
291. http://doi.org/10.1016/0165-0173(93)90013-P
SAMSHA. (2015). Medication-Assisted Treatment (MAT). Retrieved April 12, 2016,
from http://www.samhsa.gov/medication-assisted-treatment
	
  

35	
  

	
  
Stojek, M. K., Fischer, S., & MacKillop, J. (2015). Stress, cues, and eating behavior.
Using drug addiction paradigms to understand motivation for food. Appetite, 92,
252–260. http://doi.org/10.1016/j.appet.2015.05.027
Stotts, A. L., Dodrill, C. L., & Kosten, T. R. (2009). Opioid Dependence Treatment:
Options In Pharmacotherapy. Expert Opinion on Pharmacotherapy, 10(11),
1727–1740. https://doi.org/10.1517/14656560903037168
Sussman, S., & Black, D. (2008). Substitute addiction: A concern for researchers and
practitioners. Journal of Drug Education, 38(2), 167–180.
Thomas, C. P., Fullerton, C. A., Kim, M., Montejano, L., Lyman, D. R., Dougherty, R.
H., Delphin-Rittmon, M. E. (2014). Medication-assisted treatment with
buprenorphine: assessing the evidence. Psychiatric Services (Washington, D.C.),
65(2), 158–170. https://doi.org/10.1176/appi.ps.201300256
Truven Health Analytics. (2011). Methadone. Retrieved from
http://www.dynamed.com/login.aspx?direct=true&site=DynaMed&id=233079.
Umbricht, A., Schroeder, J. R., Antoine, D. G., Tompkins, D. A., Barnhouser, C., Strain,
E. C., & Bigelow, G. (2015). Topiramate effect on weight gain during methadone
maintenance. Drug and Alcohol Dependence, 156, e227.
http://doi.org/10.1016/j.drugalcdep.2015.07.611	
  
Vermont Department of Health. (2014). The challenge of opiate addiction. Retrieved
March 22, 2016, from
http://healthvermont.gov/adap/treatment/opioids/documents/OpioidChallengeBrie
f_June2014.pdf
Volkow, N. D., Wang, G.-J., Fowler, J. S., Logan, J., Jayne, M., Franceschi, D., Wong,
C., Gatley, S. J., Gifford, A. N., Ding, Y.-S. and Pappas, N. (2002).
“Nonhedonic” food motivation in humans involves dopamine in the dorsal
striatum and methylphenidate amplifies this effect. Synapse, 44: 175–180.
doi: 10.1002/syn.10075
White, M. A., Whisenhunt, B. L., Williamson, D. A., Greenway, F. L., & Netemeyer, R.
G. (2002). Development and Validation of the Food-Craving Inventory. Obesity
Research, 10(2), 107–114. https://doi.org/10.1038/oby.2002.17
Willenbring, M. L., Morley, J. E., Krahn, D. D., Carlson, G. A., Levine, A. S., & Shafer,
R. B. (1989). Psychoneuroendocrine effects of methadone maintenance.
Psychoneuroendocrinology, 14(5), 371–391. http://doi.org/10.1016/03064530(89)90007-3

	
  

36	
  

	
  
Yaksh T.L., Wallace M.S. (2011). Opioids, analgesia, and pain management. In Brunton
L.L., Chabner B.A., Knollmann B.C. (Eds), Goodman & Gilman's: The
Pharmacological Basis of Therapeutics, 12e. Retrieved May 18,
2016 fromhttp://accessmedicine.mhmedical.com.ezproxy.uvm.edu/content.aspx?b
ookid=1613&Sectionid=102158872.

	
  

37	
  

